Indication

For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.

Medicine details

Medicine name:
ustekinumab (Stelara)
SMC ID:
SMC2250
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Gastro-intestinal system
Submission type
Full
Status
Publication due date:
13 April 2020
SMC meeting date:
03 March 2020
Patient group submission deadline:
03 February 2020